Skip to main content
NewslettersWatchlist

Briacell Therapeutics Corp(BCT-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.88
Day High0.97
Open:0.97
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference
GlobeNewswire
BriaCell Overall Survival Data Selected for Spotlight Poster at 2024 San Antonio Breast Cancer Symposium®, December 10 – 13
GlobeNewswire
BriaCell Reports Outperforming Metastatic Breast Cancer Patients and Standard-Beating Survival Data
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
GlobeNewswire
BriaCell Provides Phase 3 Clinical Engagement Update in Metastatic Breast Cancer Pivotal Study
GlobeNewswire
BriaCell Therapeutics Announces Closing of $5 Million Offering
GlobeNewswire
BriaCell Therapeutics Announces $5 Million Offering
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
Baystreet
Stocks in play: BriaCell Therapeutics Corp.
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Top 10 Undervalued Healthcare Sector Stocks on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
AI-generated - The Globe and Mail
BriaCell Therapeutics: Bottom 25 Performing Stocks Year-to-Date on TSX (BCT)
The Globe and Mail
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT)
The Globe and Mail
BriaCell Therapeutics: Stocks Undervalued by Analyst Consensus on TSX (BCT)
BayStreet.ca
Five Top Companies Fighting for the Treatment of Metastatic Breast Cancer

Profile

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.